Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl) methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage

Journal of Controlled Release

Volumn 174, Issue 1, 2014, Pages 81-87

  Nakamura, Hideaki ^a   Etrych, Tomas ^b   Chytil, Petr ^b   Ohkubo, Manami ^a   Fang, Jun ^a   Ulbrich, Karel ^b   Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Acid cleavable linkage; EPR effect; HPMA polymer conjugate; Hydrazone; Pirarubicin (THP); Tumor selectivity

Indexed keywords

BIOCHEMISTRY; CONTROLLED DRUG DELIVERY; HISTOLOGY; TARGETED DRUG DELIVERY;

EPR EFFECT; HYDRAZONES; PIRARUBICIN (THP); POLYMER CONJUGATE; TUMOR SELECTIVITIES;

TUMORS;

ACID; DOXORUBICIN; HYDRAZONE DERIVATIVE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PIRARUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG SELECTIVITY; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HEART; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE; LUNG; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SARCOMA 180; SURVIVAL RATE; WEIGHT CHANGE;

ACID-CLEAVABLE LINKAGE; EPR EFFECT; HPMA POLYMER CONJUGATE; HYDRAZONE; PIRARUBICIN (THP); TUMOR SELECTIVITY;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; HELA CELLS; HUMANS; MALE; MICE; NEOPLASMS; POLYMERS; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 84888784541     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.11.011     Document Type: Article

References (25)

1. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 12 Pt 1 1986 6387 6392 (Pubitemid 17221789)
2. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 3 2011 136 151
3. H. Maeda Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 88 3 2012 53 71
4. T. Lammers Drug delivery research in Europe J. Control. Release 161 2 2012 151
5. V. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Deliv. Rev. 63 3 2011 131 135
6. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, and H. Maeda Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues Jpn. J. Cancer Res. 89 3 1998 307 314 (Pubitemid 28197296)
7. W.C. Zamboni Liposomal, nanoparticle, and conjugated formulations of anticancer agents Clin. Cancer Res. 11 23 2005 8230 8234 (Pubitemid 41746931)
8. E. Fleige, M.A. Quadir, and R. Haag Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications Adv. Drug Deliv. Rev. 64 9 2012 866 884
9. W.C. Zamboni Concept and clinical evaluation of carrier-mediated anticancer agents Oncologist 13 3 2008 248 260 (Pubitemid 351679900)
10. M.J. Vicent, R. Tomlinson, S. Brocchini, and R. Duncan Polyacetal-diethylstilboestrol: a polymeric drug designed for pH-triggered activation J. Drug Target. 12 8 2004 491 501 (Pubitemid 40081304)
11. Y. Bae, N. Nishiyama, S. Fukushima, H. Koyama, M. Yasuhiro, and K. Kataoka Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy Bioconjug. Chem. 16 1 2005 122 130 (Pubitemid 40129685)
12. Y. Bae, N. Nishiyama, and K. Kataoka In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments Bioconjug. Chem. 18 4 2007 1131 1139 (Pubitemid 47122634)
13. B. Rihova, T. Etrych, M. Pechar, M. Jelinkova, M. Stastny, O. Hovorka, M. Kovar, and K. Ulbrich Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes J. Control. Release 74 1-3 2001 225 232 (Pubitemid 32727624)
14. S.O. Doronina, B.E. Toki, M.Y. Torgov, B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc, R.P. Gearing, T.D. Bovee, C.B. Siegall, J.A. Francisco, A.F. Wahl, D.L. Meyer, and P.D. Senter Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21 7 2003 778 784 (Pubitemid 36791396)
15. T. Etrych, M. Jelinkova, B. Rihova, and K. Ulbrich New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties J. Control. Release 73 1 2001 89 102 (Pubitemid 32406104)
16. H.S. Yoo, E.A. Lee, and T.G. Park Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages J. Control. Release 82 1 2002 17 27 (Pubitemid 34775044)
17. J. Yang, H. Chen, I.R. Vlahov, J.X. Cheng, and P.S. Low Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates J. Pharmacol. Exp. Ther. 321 2 2007 462 468 (Pubitemid 46624512)
18. H. Umezawa, Y. Takahashi, M. Kinoshita, H. Naganawa, T. Masuda, M. Ishizuka, K. Tatsuta, and T. Takeuchi Tetrahydropyranyl derivatives of daunomycin and adriamycin J. Antibiot (Tokyo) 32 10 1979 1082 1084 (Pubitemid 10071255)
19. S. Kunimoto, K. Miura, Y. Takahashi, T. Takeuchi, and H. Umezawa Rapid uptake by cultured tumor cells and intracellular behavior of 4′-O-tetrahydropyranyladriamycin J. Antibiot (Tokyo) 36 3 1983 312 317 (Pubitemid 13123780)
20. H. Hatakeyama, H. Akita, K. Kogure, M. Oishi, Y. Nagasaki, Y. Kihira, M. Ueno, H. Kobayashi, H. Kikuchi, and H. Harashima Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid Gene Ther. 14 1 2007 68 77 (Pubitemid 44942867)
21. T. Masuda, H. Akita, K. Niikura, T. Nishio, M. Ukawa, K. Enoto, R. Danev, K. Nagayama, K. Ijiro, and H. Harashima Envelope-type lipid nanoparticles incorporating a short PEG-lipid conjugate for improved control of intracellular trafficking and transgene transcription Biomaterials 30 27 2009 4806 4814
22. L.E. Gerweck, S.V. Kozin, and S.J. Stocks The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells Br. J. Cancer 79 5-6 1999 838 842 (Pubitemid 29082114)
23. A. Malugin, P. Kopeckova, and J. Kopecek Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells J. Control. Release 124 1-2 2007 6 10 (Pubitemid 350088209)
24. K. Nagai, K. Nagasawa, A. Ishimoto, and S. Fujimoto Pirarubicin is taken up by a uridine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells Cancer Chemother. Pharmacol. 51 6 2003 512 518 (Pubitemid 36791678)
25. H. Lu, C. Chen, and C. Klaassen Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice Drug Metab. Dispos. 32 12 2004 1455 1461 (Pubitemid 39564566)